RSS  JOBS   SITE MAP 
 HOME 
PHARMA
BIO TECHNOLOGY
MEDICAL TECHNOLOGY
 RESOURCE CENTER 
 SUBSCRIBE 
 SUBSCRIBE ASIA DIGEST 
  Friday, September 3, 2010 SEARCH     
 
 
BIO AUSTRALIA
BIO CHINA
BIO INDIA
BIO INDONESIA
BIO JAPAN
BIO KOREA
BIO MALAYSIA
BIO NEW ZEALAND
BIO PHILIPPINES
BIO SINGAPORE
BIO TAIWAN
BIO THAILAND
 
 
Get the latest news on life sciences in your mail box
Name
E-Mail Id
 
 
Advertisement



















 
Pharma  News  Story
Sun Pharma to resubmit ANDA

Bangalore, Nov 28, 2008: India’s Sun Pharmaceutical will have to submit a new ANDA for the approval of its generic venlafaxine extended release tablets.
 
In the petition granted by the USFDA, Abbreviated New Drug Application (ANDA) for tablets citing Wyeth’s ‘Effexor XR’ capsules as the reference will not be accepted.
 
The company had previously filed an ANDA for a bio-equivalent of ‘Effexor XR’ capsules. The FDA has concluded that an ANDA for venlafaxine extended release tablets should reference US-based company Osmotica’s product and not Wyeth’s.
 
Such amendments to a pending ANDA are not permitted as per FDA and thus the company will have to resubmit the ANDA for venlafaxine extended release tablets.

© BioSpectrum Bureau
  Email this articleComment on this article   Print this article
 
Advertisement





 
   
 
Google
BioSpectrumAsia.com BioSpectrumIndia.com Web

About BioSpectrum | How to Advertise | Jobs at BioSpectrum | Jobs at CyberMedia | Contact Us | Privacy Statement



CyberMedia Network Websites


[Voice&Data]  [PCQuest]  [CIOL]  [Dataquest]  [Living Digital]  [IDC India]
[DQ Channels]  [The DQweek]  [DARE]  
[CyberMedia Events] [CyberMedia Digital]  [Cyber Astro]  [CyberMedia India]  [Global Services]  [BioSpectrum]

 
Copyrights are reserved for BioSpectrum ; Designed by : Altered Black